Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 213 | 52 | 148 |
| Samples | 195 | 49 | 142 |
| Peptides | 165 | 40 | 120 |
Function
NKX3-2 · NK3 homeobox 2
This gene encodes a member of the NK family of homeobox-containing proteins. The encoded protein may play a role in skeletal development. [provided by RefSeq, Jul 2008]
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000382438 | P78367 | 213 | 165 |
Gene Properties
Recurrent Mutations
All 165 amino-acid changes on canonical ENST00000382438 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NKX3-2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NKX3-2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 13/1390 1% |
| Gastric Carcinoma | 1/74 1% | 23/1809 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 5/612 1% |
| Colorectal Carcinoma | 8/143 6% | 22/3239 1% |
| Melanoma | 5/210 2% | 12/1899 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 5/810 1% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Neuroendocrine Tumour | 1/154 1% | 3/577 1% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 7/1592 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 11/2550 0% |
| Hepatocellular Carcinoma | 0/46 0% | 7/2210 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Head and Neck Carcinoma | 3/85 4% | 2/1574 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Breast Carcinoma | 1/144 1% | 8/3264 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Kidney Carcinoma | 2/85 2% | 2/1862 0% |
| Prostate Carcinoma | 1/13 8% | 3/2105 0% |
| B-Lymphoblastic Leukemia | 3/55 5% | 2/2640 0% |
| Other Solid Cancers | 0/94 0% | 2/1515 0% |
| Glioma | 0/52 0% | 2/2127 0% |
| Ovarian Carcinoma | 1/109 1% | 0/998 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 1/2534 0% |
| Other Blood Cancers | 1/61 2% | 1/2725 0% |
Mutation Distribution
Where NKX3-2 is mutated · all tissues, split by cell line vs tissue
How many mutations in NKX3-2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 39 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 213 mutations in NKX3-2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|